Successful liver transplant after Yttrium-90 microsphere radioembolization combined with targeted and immunotherapy： a case report and literature review

doi:10.3969/j.issn.1009-976X.2024.01.011

Abstract

Abstract: Objective To discuss successful liver transplantation in advanced hepatocellular carcinoma patients after yttrium-90 microsphere radioembolization （Y90-RE） combination of targeted and immunotherapy： a clinical case report and literature review. Methods A retrospective analysis of a case of advanced hepatocellular carcinoma patient who underwent successful liver transplantation after Y90-RE combination of targeted and immunotherapy at our center was performed. The relevant treatment methods and postoperative disease changes were analyzed, and the latest domestic and international literature progress was summarized. Results The patient was a 41-year-old middle-aged man. After Y90-RE combination target-immune therapy, he underwent liver transplantation. During the perioperative period, human immunoglobulin pulse therapy was administered, and a combined immunosuppressive scheme of tacrolimus and glucocorticoids was given early after surgery. The patient′s liver function gradually improved within 2 weeks after surgery. However, mild elevations of transaminases were detected on the 15th and 68th days after surgery, accompanied by mild acute rejection identified by liver biopsy. Both episodes were resolved by strengthening immunosuppressive treatment. Now, after 6 months of follow-up, the patient′s liver function is normal, and no tumor recurrence is observed. Conclusion Y90-RE combined target-immune therapy can provide a treatment option for advanced hepatocellular carcinoma patients.

Key words: liver cancer, liver transplantation, Yttrium-90 microsphere radioembolization, targeted immunotherapy, rejection reaction

摘要： 目的探讨晚期肝癌经钇-90微球放射栓塞（Y90-RE）联合靶向和免疫治疗后成功肝移植治疗的临床资料并复习相关文献。方法回顾性分析我中心一例晚期肝癌患者经Y90-RE联合靶向和免疫治疗后成功行肝移植治疗,对相关治疗方法及术后病情变化特点进行分析,并总结国内外最新文献进展。结果患者为41岁中年男性,经Y90-RE联合靶免治疗后行肝移植术,围手术期予人免疫球蛋白冲击治疗,术后早期予他克莫司+糖皮质激素联合免疫抑制方案。患者术后2周内肝功能逐渐好转后,在术后第15天和第68天出现转氨酶轻度升高,肝穿刺病理提示轻度急性排斥反应,均通过予加强免疫抑制治疗后好转。现随访6月余,肝功能正常,未见肿瘤复发。结论 Y90-RE联合靶免治疗可为晚期肝癌患者提供一种治疗选择方案。

关键词: 肝癌, 肝移植, 钇-90微球放射栓塞治疗, 靶免治疗, 排斥反应

CLC Number:

R681.5

CHEN Huan-quan, HE Cai-hua, DAI Tian-xing, HUANG Wen-sou, YUAN Feng, WANG Xiao-ming, LUO Yan-jun, WANG Guo-ying. Successful liver transplant after Yttrium-90 microsphere radioembolization combined with targeted and immunotherapy： a case report and literature review[J]. Lingnan Modern Clinics In Surgery, 2024, 24(01): 69-75.

陈焕权, 何才华, 代天星, 黄文薮, 袁峰, 王晓明, 罗燕君, 汪国营. 钇-90微球放射栓塞联合靶向和免疫治疗后成功肝移植：一例报道并文献复习[J]. 岭南现代临床外科, 2024, 24(01): 69-75.

References

[1] 原发性肝癌诊疗指南(2022年版)[J]. 浙江实用医学, 2022, 27(6): 528-536.
[2] Fong Y.Liver Transplant Outcomes After Downstaging to Within Milan Criteria-Balancing Patient Benefit With Resource Allocation[J]. JAMA Surg, 2022, 157(9): 788-789.
[3] Vagefi PA, Parekh J, Ascher NL, et al.Outcomes with split liver transplantation in 106 recipients: the University of California, San Francisco, experience from 1993 to 2010[J]. Arch Surg, 2011, 146(9): 1052-1059.
[4] Xu DW, Wan P, Xia Q.Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: A review[J]. World J Gastroenterol, 2016, 22(12): 3325-3334.
[5] 刘召波, 武聚山, 林栋栋, 栗光明. PD-1抑制剂用于肝癌肝移植术前治疗的安全性探讨[J]. 器官移植, 2021, 12(4): 445-449.
[6] 鲁旭, 李华, 易述红,等. 介入联合仑伐替尼桥接治疗超米兰标准肝癌肝移植2例报道[J]. 岭南现代临床外科, 2021, 21(5): 507-511.
[7] Kulik LM, Atassi B, van Holsbeeck L, et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation[J]. J Surg Oncol, 2006, 94(7): 572-586.
[8] Salem R, Johnson GE, Kim E, et al.Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study[J]. Hepatology, 2021, 74(5): 2342-2352.
[9] Abdel-Rahman OM, Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma [J]. Cochrane Database Syst Rev, 2016, 2: Cd011313.
[10] Feng X, Zhang L, Niu H, et al.Selective internal radiation therapy with yttrium-90 resin microspheres followed by anatomical hepatectomy: A potential curative strategy in advanced hepatocellular carcinoma[J]. Asia Pac J Clin Oncol, 2024,20(2):319-322.
[11] Edeline J, Gilabert M, Garin E, et al.Yttrium-90 microsphere radioembolization for hepatocellular carcinoma[J]. Liver Cancer, 2015, 4(1): 16-25.
[12] Ettorre GM, Levi Sandri GB, Laurenzi A, et al.Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation[J]. World J Surg, 2017, 41(1): 241-249.
[13] Ali R, Riaz A, Gabr A, et al.Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection[J]. Eur J Nucl Med Mol Imaging, 2017, 44(13): 2195-2202.
[14] Meerun MA, Allimant C, Rivière B, et al.Large, multifocal or portal vein-invading hepatocellular carcinoma (HCC) downstaged by Y90 using personalized dosimetry: safety, pathological results and outcomes after surgery[J]. Hepatobiliary Surg Nutr, 2023, 12(3): 351-365.
[15] 田亚, 曹洪庆, 赵德贞. 钇[90Y]微球放射栓塞治疗在中晚期肝细胞癌中的临床应用[J]. 中国现代医药杂志, 2024, 26(1): 101-106.
[16] Alghamdi S, Al-Hamoudi W.Hepatocellular Carcinoma: The Role of Immunotherapy and Transplantation in the Era of Transplant Oncology[J]. Cancers (Basel), 2023, 15(21):5115.
[17] Lei J, Wang W, Yan L.Surgical resection versus open-approach radiofrequency ablation for small hepatocellular carcinomas within Milan criteria after successful transcatheter arterial chemoembolization[J]. J Gastrointest Surg, 2013, 17(10): 1752-1759.
[18] Schwacha-Eipper B, Minciuna I, Banz V, Dufour JF.Immunotherapy as a Downstaging Therapy for Liver Transplantation[J]. Hepatology, 2020, 72(4): 1488-1490.
[19] Wassmer CH, El Hajji S, Papazarkadas X, et al.Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data[J]. Cancers (Basel), 2023, 15(18):4574.
[20] Llovet JM, Kudo M, Merle P, et al.Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2023, 24(12): 1399-1410.
[21] 梁雄, 伍楚蓉, 唐武兵,等. 介入治疗联合仑伐替尼及信迪利单抗治疗中晚期肝癌的近期疗效观察[J]. 现代肿瘤医学, 2023, 31(20): 3812-3817.
[22] 孙正路, 王航宇, 张艳停. 介入治疗联合仑伐替尼及信迪利单抗治疗中晚期肝癌效果观察[J]. 罕少疾病杂志, 2024, 31(2): 103-105.
[23] 王俊洁, 徐龙, 袁国盛,等. 信迪利单抗联合仑伐替尼二线治疗不可切除肝细胞肝癌的临床疗效及安全性[J]. 实用医学杂志, 2022, 38(9): 1130-1135.
[24] 刘振华, 汤可立, 陈根,等. PD-1抑制剂在肝癌肝移植术前使用的安全性分析[J]. 实用器官移植电子杂志, 2022, 10(6): 516-520.
[25] Wang T, Chen Z, Liu Y, et al.Neoadjuvant programmed cell death 1 inhibitor before liver transplantation for HCC is not associated with increased graft loss[J]. Liver Transpl, 2023, 29(6): 598-606.
[26] Kim Y, Stahl CC, Makramalla A, et al.Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria[J]. Surgery, 2017, 162(6): 1250-1258.
[27] Salem R, Gordon AC, Mouli S, et al. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma [J]. Gastroenterology, 2016, 151(6): 1155-1163.e1152.
[28] Kishore S, Friedman T, Madoff DC.Update on Embolization Therapies for Hepatocellular Carcinoma[J]. Curr Oncol Rep, 2017, 19(6): 40.
[29] Gabr A, Kulik L, Mouli S, et al.Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort[J]. Hepatology, 2021, 73(3): 998-1010.
[30] Somma F, Stoia V, Serra N, et al.Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival[J]. PLoS One, 2019, 14(5): e0216935.
[31] Kousik V, Promila P, Verma R, Gupta A.Role of yttrium-90 in the management of unresectable hepatocellular carcinoma and hepatic metastases[J]. Indian J Gastroenterol, 2016, 35(3): 179-185.
[32] Kulik L, Vouche M, Koppe S, et al.Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma[J]. J Hepatol, 2014, 61(2): 309-317.
[33] Vouche M, Kulik L, Atassi R, et al.Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib[J]. Hepatology, 2013, 58(5): 1655-1666.
[34] Yu S, Yu M, Keane B, et al.A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma[J]. Oncologist, 2024,29(3):270-e413.
[35] Lee YB, Nam JY, Cho EJ, et al.A Phase I/IIa Trial of Yttrium-90 Radioembolization in Combination with Durvalumab for Locally Advanced Unresectable Hepatocellular Carcinoma[J]. Clin Cancer Res, 2023, 29(18): 3650-3658.
[36] Villalobos A, Dabbous HH, Little O, et al.Safety and Efficacy of Concurrent Atezolizumab/Bevacizumab or Nivolumab Combination Therapy with Yttrium-90 Radioembolization of Advanced Unresectable Hepatocellular Carcinoma[J]. Curr Oncol, 2023, 30(12): 10100-10110.